CellXLife
Private Company
Funding information not available
Overview
CellXLife is advancing a dendritic cell-based cancer vaccine with compelling long-term survival data from an initial Phase I trial in pediatric bone cancer. The therapy, which leverages immunological memory, demonstrated a 62.5% survival rate beyond 15 years in a small, high-risk patient cohort. The company is preparing for a Phase II trial and benefits from Orphan Drug Designation, which may facilitate a faster regulatory pathway. Its platform also has potential applications in other solid tumors, including breast, ovarian, and lung cancers.
Technology Platform
Autologous dendritic cell-based cancer vaccine designed to induce immunological memory against residual cancer cells to prevent recurrence.
Opportunities
Risk Factors
Competitive Landscape
Limited direct competition in pediatric recurrent bone sarcomas, with no new immunotherapy approvals since 2000. Broader competitive pressure exists from the wider immuno-oncology field (e.g., CAR-T, bispecifics) exploring solid tumors, though pediatric sarcomas remain a niche. Autologous cancer vaccines have historically shown modest efficacy, positioning CellXLife's differentiated protocol as a potential breakthrough.